Allogeneic Transplantation of Haematopoietic Stem Cells Following Non-myeloablative Conditioning With Melphalan, Fludarabine, Thiotepa, Rituximab and Ibritumomab Tiuxetan (Zevalin) in Patients With Aggressive Non-Hodgkin's B-cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Fludarabine; Melphalan; Rituximab; Thiotepa
- Indications Graft-versus-host disease; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms Z-RIC-Allo
- 04 May 2012 Status changed from recruiting to completed, according to the European Clinical Trials Database.
- 11 Apr 2008 New trial record.